Search for a trial

The efficacy of an antigenic marker lesion for the therapeutic effect in patients with multiple, Ta/T1, G1/G2, non-muscle invasive bladder cancer (NMIBC) treated with TUR followed by IL-2 instillation

We like to demonstrate that treatment of non-muscle invasive bladder carcinoma with incomplete TUR and IL-2 is therapeutically more effective than treatment with complete TUR and IL-2.

Reducing costs of surveillance of patients with non-muscle invasive bladder cancer.

1) To prove that it is possible to safely reduce the number of invasive cystoscopies during follow-up (FUP) of patients with NMIBC with a low/intermediate risk of recurrence or progression. 2) To prove that addition of urine tests to the follow-up…

Neurogenic bladder in children: use of feed-back tools during standard treatment with anticholinergics.

We aim to increase patient compliance by extending the existing treatment protocol of (oral or intravesical) anticholinergics plus application of CIC with the addition of bladder pressure measurement performed at home during CIC plus access to an…

a phase III randomised trial of intravesical chemotherapy vs thermo-chemotherapy in intermediate risk non-muscle invasive bladder cancer

To compare standard treatment with intravesical chemotherapy with loco-regional thermo-chemotherapy in patients with an intermediate risk non-muscle invasive urothelial carcinoma of the bladder after complete transurethral resection of the tumour(s…

The Global randomized NBi bladder cancer study
A Multi-Centre, International study to compare the use of Narrow Band Imaging (NBI) versus White light (WL) to assess recurrence of bladder cancer in terms of safety and efficacy.

To compare the recurrence rate at 1 year following Narrow Band Imaging and TURB (Arm A) with White Light Trans Urethral Resection of Bladder cancer (TURB) (Arm B) in patients with bladder cancer (NMIBC).The purpose of this study is to investigate…

A randomised controlled trial comparing physiotherapy to electromagnetic stimulation for urinary incontinence

Primary objective:Subjective improvement of urinary incontinence (PGI-I)Secondary objectives:Objective (using stress test, padtest, bladder diaries, Sandvik score) and subjective cure of incontinence (questionnaires)Complicaties en de novo…

Evaluating the Effect of Pre-TURBT Intravesical Instillation
of Mitomycin C (MMC) Mixed With TC-3 Gel
in Patients with Non Muscle Invasive Bladder Cancer (NMIBC)

Evaluation of the effect of pre-TURBT intravesical instillations of MMC mixed with TC-3 Hydrogel on bladder lesion(s) of NMIBC patients.a. Comparison of the effect of pre-TURBT instillations with MMC mixed with TC-3 Hydrogel on bladder lesion(s) to…

CAMPUR study: CAtheter Managment and diagnostics for symptomatic Postpartum Urinary Retention

To compare which treatment (indwelling catheter versus intermittend catheterisation) has the best clinical effect in women with symptomatic PUR.

A randomized controlled trial of anterior colporraphy and PerigeeTM as surgical correction of symptomatic cystocele.

To study which technique is most effective to surgically correct a symptomatic cystocele.2. To compare morbidity and post-operative recovery of anterior colporraphy and PerigeeTM.3. To compare the need for repeated pelvic floor surgery following…

Bladder training with or without PTNS(Posterior Tibial Nerve Stimulation) in the treatment of Overactive Bladder

The main objective of this study will be to assess whether an additive stimulation of the posterior tibial nerve (PTNS) in combination with bladder training has a significant reduction in frequency of micturition in patients with overactive bladder…

One day versus three day suprapubic catheterisation after vaginal prolapse surgery: a randomized controlled trial.

To determine the optimal moment to start bladder training after vaginal prolapse surgery with anterior colporrhaphy.

Shorter treatment of catheter-related urinary tract infections

The primary objective is to establish the non-inferiority of treating a symptomatic urinary tract infection in patients with a long-term indwelling catheter for 5 days, as compared to the standard duration of 10 days of therapy. Secondary objectives…

A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy

The primary objective of the entire study is to compare rogaratinib (BAY1163877) with chemotherapy (docetaxel, paclitaxel or vinflunine) in terms of prolonging the Overall survival (OS) of patients with FGFR positive urothelial carcinoma.

A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients with Advanced Solid Tumors

Determine the efficacy and safety (using objective response rate) of tremelimumab in patients with advanced solid tumors (UBC, PDAC, TNBC).

Functional near-infrared spectroscopy as biofeedback to assist pelvic floor muscle training: a randomized controlled trial.

The main aim is to study whether fNIRS is a reliable non-invasive alternative to invasive pelvic floor EMG in order to provide biofeedback during pelvic floor physical therapy in patients with SUI.

A Phase III Randomized, Open-Label, Multicenter Study to Determine the
Efficacy and Safety of Durvalumab in Combination With Tremelimumab
and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab
Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or
Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive
Bladder Cancer (VOLGA)

This study has been transitioned to CTIS with ID 2023-507342-84-00 check the CTIS register for the current data. (1) Main objective:Safety Run-In (SRI):To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC…

A Phase 1/2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab Plus Enfortumab Vedotin (EV) in Combination With Investigational Agents Versus Pembrolizumab Plus EV, as First-Line Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04): Substudy 04B

This study has been transitioned to CTIS with ID 2023-506385-30-00 check the CTIS register for the current data. Primary Part 1:-To evaluate ORR in participants treated with MK-4280A plus EV (Arm A), MK-7684A plus EV (Arm B), and pembrolizumab plus…

A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)

This study has been transitioned to CTIS with ID 2023-507187-39-00 check the CTIS register for the current data. The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk…

A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)

The current study is designed to evaluate the safety and efficacy of combination therapy with pembrolizumab + lenvatinib versus pembrolizumab + placebo in cisplatin-ineligible participants whose tumors express PD-L1 (CPS >=10) and…

A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

The primary objective of this study is to evaluate efficacy of erdafitinib versus chemotherapy orpembrolizumab in subjects with advanced urothelial cancer harboring selected FGFR aberrations whohave progressed after 1 or 2 prior treatments, at least…